-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $50

Benzinga·08/01/2025 13:20:10
Listen to the news
Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target from $52 to $50.